Core Viewpoint - The company has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) for the marketing authorization of midazolam injection, which will positively impact its international business expansion [1] Group 1 - The company's subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., is responsible for the midazolam injection that has received the approval [1] - The approval allows the company to sell midazolam injection in Germany, marking a significant step in its international market strategy [1]

Core Viewpoint - The company has received marketing authorization for midazolam injection from the German Federal Institute for Drugs and Medical Devices (BfArM), indicating a significant regulatory achievement that could enhance its market presence in Europe [1] Group 1: Regulatory Approval - The company's subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., has been granted marketing authorization for midazolam injection by BfArM [1] - The approved indications for midazolam injection include: 1) conscious sedation before, during, and after diagnostic or therapeutic procedures, with or without local anesthesia; 2) preoperative medication for adult anesthesia induction, anesthesia induction, and use in combination with other anesthetics as a sedative; preoperative medication for pediatric anesthesia induction; 3) sedation in the Intensive Care Unit (ICU) [1]

Group 1 - The board of directors of Renfu Pharmaceutical Group Co., Ltd. held its fourth meeting of the eleventh session on December 5, 2025, with all nine directors present, ensuring compliance with legal and regulatory requirements [2][4] - The board approved the establishment of a supervision department to enhance internal supervision, improve compliance governance, and mitigate integrity risks, thereby ensuring effective execution of the company's strategic decisions [3] - The board also approved the formulation of the "Risk Management and Internal Control Management System" and the "Legal Compliance Affairs Management System," both of which will be disclosed on the Shanghai Stock Exchange website [5][6] Group 2 - All resolutions passed with unanimous support, receiving 9 votes in favor, with no votes against or abstentions [4][5][6] - The establishment of the supervision department and the new management systems reflect the company's commitment to stringent governance and risk management practices [3][5][6] - The meeting was chaired by Chairman Deng Weidong, indicating strong leadership and oversight within the company [2]

Group 1 - The core point of the article is that Renfu Pharmaceutical (SH 600079) held its 11th fourth board meeting on December 5, 2025, to discuss the establishment of a legal compliance management system [1] - For the year 2024, Renfu Pharmaceutical's revenue composition is as follows: pharmaceuticals account for 56.01%, pharmaceutical wholesale and related businesses account for 43.8%, and other businesses account for 0.19% [1] - As of the time of reporting, Renfu Pharmaceutical has a market capitalization of 30.4 billion yuan [1]

第十一届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法 律责任。 一、董事会会议召开情况 人福医药集团股份公司（以下简称"人福医药"或"公司"）第十一届董事会第 四次会议于 2025 年 12 月 5 日（星期五）上午 9:00 在公司会议室以现场结合通讯方式 召开，会议通知已于 2025 年 11 月 29 日通过邮件的方式送达各位董事。会议应到董 事九名，实到董事九名，本次会议由邓伟栋董事长主持。本次董事会会议的召集、召 开符合有关法律、行政法规、部门规章、规范性文件和《公司章程》的规定，所做决 议合法有效。 二、董事会会议审议情况 （一）审议通过《关于设立监察部的议案》 证券代码：600079 证券简称：人福医药 编号：临 2025-126 人福医药集团股份公司 为深入贯彻落实全面从严治党要求，强化公司内部监督体系，提升合规治理水平， 防范廉洁风险，保障公司战略部署和重大决策有效执行，在公司组织架构中设立监察 部，作为履行纪检监察职能的专职机构，并授权管理层按程序推进机构设置、人员配 备及相关制度建设工 ...

第四条 各单位法律合规工作的基本原则为： 1 （一） 依法合规维护人福医药及本单位最大利益原则； （二） 早期介入、预防风险为主原则； （三） 独立工作、不受干扰原则； （四） 防范法律合规风险和把握商业机会综合考虑原 则； 人福医药集团股份公司 法律合规事务管理制度 （2025 年 12 月版） 第一章 总 则 第一条 为加强人福医药集团股份公司（下称"人福医 药"或"公司"）法治建设，完善法律合规事务管理，不断 提升依法治企和合规管理水平，建立健全人福医药法治工作 体系，实现人福医药法律合规管理的制度化、规范化、系统 化、数智化，切实维护人福医药合法权益，结合公司实际， 制定本制度。 第二条 本制度适用于人福医药及人福医药下属全资、 控股及其受托管理的公司及其他所属单位。 第三条 各单位法律合规工作的宗旨是：围绕人福医药 建设具有全球竞争力的世界一流生命科技企业的战略目标， 落实本单位主要负责人履行法治建设第一责任人职责，完善 法治建设顶层设计，建立和完善适应本单位发展和现代企业 治理结构需要的法治工作专业体系和法律合规风险防控机制， 提供适应本单位发展战略和经营管理需要的法律合规支撑和 保障。 （五） ...

人福医药集团股份公司 风险管理与内部控制管理制度 （2025 年 12 月版） 第一章 总则 第一条 为建立规范、有效的风险管理体系，促进提高风 险防范能力，提高经营管理水平，根据《中华人民共和国公司 法》《企业内部控制基本规范》（财会〔2008〕7 号）等法律 法规、规范性文件有关规定，结合人福医药集团股份公司（下 称"人福医药"）实际，制定本制度。 第二条 本制度适用于人福医药及下属全资、控股、实际 控制及其受托管理的公司及其他所属单位。 人福医药下属境外企业在满足相关法律法规、监管要求的 前提下，可结合自身经营管理实际，根据本制度制定并完善自 身风险管理与内部控制管理制度。 第三条 本制度所称风险是指未来的不确定性对人福医药 实现经营目标的影响；风险管理是指各单位围绕总体经营目标， 建立健全风险管理体系，包括风险管理策略、风险监测预警机 制、风险应对措施，从而为实现风险管理总体目标提供合理保 证的过程和方法；内部控制是指由各单位治理层、管理层及全 体员工实施的，通过在管理环节和经营过程中构建良好的内部 环境、执行基本流程，从而实现控制目标的过程。 第四条 人福医药风险管理工作的总体目标是： 1 以保障人 ...

Group 1 - Dongfang Electric announced that three executives plan to reduce their holdings by a total of no more than 30,000 shares due to personal financial needs [1] - Yahu Pharmaceutical's APL-1401 clinical trial data was presented at the 19th European Colorectal Congress, indicating progress in treating moderate to severe ulcerative colitis [1] - Guizhou Bai Ling's actual controller is under investigation by the China Securities Regulatory Commission for insider trading and information disclosure violations [3] Group 2 - Bairen Medical's ePTFE pericardial membrane product has been approved for registration, ending the reliance on imports for this product in the domestic market [4] - Qianxin received approval for a total of 2 billion yuan in technology innovation bonds, with plans to issue medium-term notes and short-term financing bonds [6] - Tengjing Technology's shareholder plans to reduce holdings by no more than 1.96% of the company's shares [7] Group 3 - Yuntianhua's subsidiary is required to pay 386 million yuan in overdue taxes and penalties, which will impact the company's net profit for 2025 [8] - Jianyou Pharmaceutical's propofol emulsion injection has received FDA approval in the United States [9] - Suzhou Gaoxin successfully acquired land use rights for a residential project for 360 million yuan [9] Group 4 - Chalco International's subsidiary won a bid for a 3.03 billion yuan electrolytic aluminum project [11] - Tai Long Pharmaceutical's stock will continue to be suspended due to potential changes in control as the major shareholder is planning a share transfer [12] - Qianli Technology reported a 63.44% year-on-year increase in automobile sales for November, although new energy vehicle sales decreased by 43.98% [13] Group 5 - Fosun Pharma's innovative drug FXS0887 has received approval for a Phase I clinical trial for advanced malignant solid tumors [14] - Guoen Co. has obtained approval for a project to produce 20,000 square meters of aviation-grade acrylic glass, with a total investment of 560 million yuan [15] - Guofa Co.'s chairman resigned due to personal reasons [17] Group 6 - Shanghai Construction won a bid for a state-owned construction land use right for 264 million yuan [18] - Weixin Kang's subsidiary received approval for a clinical trial of lidocaine cream for local anesthesia [20] - Sanxing Medical's subsidiary is a candidate for a 152 million yuan transformer procurement project for the State Grid [20] Group 7 - People's Daily announced the resignation of its president due to work changes, while retaining other leadership roles [21] - Beibu Gulf Port reported a 0.29% year-on-year increase in cargo throughput for November [22] - Chongqing Construction won three engineering projects with a total value of approximately 2.773 billion yuan [23] Group 8 - Xingyu Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange [24] - Huajian Group signed a design contract worth 160 million yuan for a comprehensive project [25] - Wankai New Materials plans to invest 350 million yuan in a technical transformation project for producing 100,000 tons of adipic acid [26] Group 9 - Kaipuyun received a government subsidy of 18 million yuan, which is 87.43% of its net profit for the last audited fiscal year [28] - Ningbo Port expects a 10.8% year-on-year increase in container throughput for November [30] - An Cai High-Tech plans to invest 498 million yuan to upgrade its photovoltaic glass production line [32] Group 10 - Shunhao Co. stated that its existing business has not generated synergies with the rail business, which faces various risks [34] - Yihualu plans to publicly transfer 35% of its stake in Liaoyun Company [35] - ST Wanfang's shareholder plans to reduce holdings by no more than 3% of the company's shares [36] Group 11 - Youyou Food's shareholder plans to reduce holdings by no more than 110,000 shares [38] - Hengtong Optic-Electric's incentive fund has spent 49.98 million yuan to purchase company shares [41] - Zoli Pharmaceutical plans to issue convertible bonds to raise no more than 1.556 billion yuan for various projects [42]

Core Points - The Medical Health R Index (480016) closed at 7284.72 points, down 0.42%, with a trading volume of 17.046 billion yuan and a turnover rate of 0.61% [1] - Among the index constituents, 23 stocks rose while 26 fell, with TeBao Bio leading the gainers at 2.85% and Renfu Pharmaceutical leading the decliners at 3.33% [1] Index Constituents Summary - The top ten constituents of the Medical Health R Index include: - WuXi AppTec (sh603259) with a weight of 13.66%, latest price at 87.62, down 2.01%, and a market cap of 261.437 billion yuan [1] - Hengrui Medicine (sh600276) with a weight of 11.00%, latest price at 60.97, down 0.25%, and a market cap of 404.670 billion yuan [1] - Mindray Medical (sz300760) with a weight of 7.57%, latest price at 199.50, down 0.56%, and a market cap of 241.882 billion yuan [1] - United Imaging Healthcare (sh688271) with a weight of 4.27%, latest price at 128.88, up 0.13%, and a market cap of 106.217 billion yuan [1] - Pianzai Shou (sh600436) with a weight of 3.48%, latest price at 171.48, up 1.33%, and a market cap of 103.457 billion yuan [1] - Aier Eye Hospital (sz300015) with a weight of 3.42%, latest price at 11.35, down 1.30%, and a market cap of 105.843 billion yuan [1] - Kelun Pharmaceutical (sz002422) with a weight of 2.59%, latest price at 34.00, down 0.03%, and a market cap of 54.334 billion yuan [1] - Xinhecheng (sz002001) with a weight of 2.42%, latest price at 24.44, up 0.20%, and a market cap of 75.114 billion yuan [1] - Fosun Pharma (sh600196) with a weight of 2.39%, latest price at 27.05, down 0.15%, and a market cap of 72.235 billion yuan [1] - Ziji Shenzhou (sh688235) with a weight of 2.27%, latest price at 275.20, down 1.59%, and a market cap of 423.995 billion yuan [1] Capital Flow Analysis - The Medical Health R Index constituents experienced a net outflow of 1.159 billion yuan from institutional investors, while retail investors saw a net inflow of 999 million yuan [1] - Detailed capital flow for specific stocks shows: - Health元 (600380) had a net inflow of 34.2431 million yuan from institutional investors [2] - Hengrui Medicine (600276) had a net inflow of 29.9909 million yuan from institutional investors [2] - Long Spring High-tech (000661) had a net inflow of 19.8154 million yuan from institutional investors [2] - The index constituents underwent adjustments, adding four new stocks and removing one [2]

Policy Trends - In 2024, the total number of medical consultations in China reached 10.15 billion, an increase of 600 million from the previous year, with a life expectancy of 79.0 years and a maternal mortality rate of 14.3 per 100,000 [1] - The total number of medical institutions in China reached 1,093,551 by the end of 2024, an increase of 22,766 from the previous year, including 38,710 hospitals [1] - The number of health technicians in China reached 13.02 million, an increase of 531,000 (4.3%) from the previous year, with 9.37 million working in hospitals [1] Healthcare Costs - The average hospitalization cost in hospitals for 2024 was 9,870 yuan, a decrease of 4.3% from the previous year, while the average outpatient cost was 361 yuan, down 0.2% [2] - The total healthcare expenditure in China for 2024 was approximately 9,089.55 billion yuan, with government spending accounting for 24.9%, social spending for 47.6%, and personal spending for 27.5% [2] - The per capita healthcare expenditure was 6,454.4 yuan, with total healthcare expenditure constituting 6.7% of GDP [2] Pharmaceutical Developments - The National Medical Insurance Administration launched a drug price registration and inquiry service, allowing pharmaceutical companies to self-declare drug prices for public access [3] - Renfu Pharmaceutical announced the withdrawal of its application for the registration of a recombinant plasmid-hepatocyte growth factor injection, which had a cumulative R&D investment of approximately 160 million yuan [4] - Hengrui Medicine received acceptance for its application for the marketing authorization of remimazolam tosylate for sedation during mechanical ventilation in intensive care [4] Investment Activities - China Resources Sanjiu established a biopharmaceutical fund in Hohhot with a total investment of 500 million yuan, focusing on private equity investments and asset management [5] - Zhaoli Pharmaceutical plans to raise up to 1.556 billion yuan through convertible bonds for the development of an intelligent traditional Chinese medicine health factory and other projects [6] Global Health Issues - The World Health Organization reported that reductions in international aid are impacting global HIV prevention efforts, with significant challenges ahead for AIDS response programs [7] Regulatory Actions - Jiangsu Wuzhong received a delisting notice from the Shanghai Stock Exchange due to major violations, including concealing changes in actual control and severe financial fraud [8] - The company is set to enter a delisting transition period on December 9, 2025, with the last trading day expected to be December 29 [8]